ArticleEuropean radiology2026
MRI assessment of tumor behavior in desmoid-type fibromatosis during active surveillance.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine whether MRI findings are associated with tumor behavior in desmoid-type fibromatosis (DF) during active surveillance. MATERIALS AND
methodsThis single-center retrospective study included patients with histopathologically confirmed DF who underwent active surveillance between January 2008 and March 2024. Tumor behavior was classified by percentage monthly change in tumor volume (PMCV) as growth ( > 1%), stable ( -1% to +1%), or shrinkage (<-1%). Longitudinal analysis included 61 observation intervals derived from 85 MRI examinations; a separate patient-based analysis included baseline MRI examinations from 24 patients. MRI findings included qualitative features, whole-tumor T2 ratio, whole-tumor apparent diffusion coefficient (ADC), and semiautomated three-dimensional volumetry. Mixed-effects logistic regression models were used for longitudinal analysis, and interobserver agreement was assessed.
resultsTwenty-four patients with 85 MRI examinations were included. PMCV was calculated for 61 observation intervals: 9 shrinkage, 13 stable, and 39 growth. No qualitative MRI feature, including margin definition, extensive T2 hyperintensity, band sign on T1- or T2-weighted imaging, tail sign, Yin-Yang sign, or dynamic contrast-enhanced MRI pattern, was significantly associated with interval tumor behavior. Neither whole-tumor T2 ratio nor whole-tumor ADC was significantly associated with growth or shrinkage relative to stability. Interobserver agreement ranged from substantial to almost perfect for qualitative features and was excellent for quantitative measurements.
conclusionNo evaluated MRI feature was significantly associated with tumor behavior in DF during active surveillance, suggesting limited value of MRI as a standalone predictor. KEY POINTS: Question Can MRI help predict tumor behavior during active surveillance in patients with DF, given the lack of established imaging predictors? Findings No evaluated MRI feature, including qualitative findings, whole-tumor T2 ratio, or whole-tumor ADC value, was significantly associated with tumor behavior during active surveillance. Clinical relevance Although MRI remains essential for monitoring DF, its standalone value for predicting tumor behavior during active surveillance may be limited.
Indexed as
Identifiers
42469534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.